scholarly journals Effect of the discontinuation of long-term sulfonylurea treatment on blood glucose and insulin secretion in noninsulin-dependent diabetes mellitus.

1982 ◽  
Vol 29 (1) ◽  
pp. 41-47 ◽  
Author(s):  
SEIICHI SUMI ◽  
KIKUO ICHIHARA ◽  
KYOHEI NONAKA ◽  
SEIICHIRO TARUI
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Secretion ◽  
Blood Glucose ◽  
Dependent Diabetes Mellitus

Propranolol does not inhibit sulphonylurea-stimulated insulin secretion in patients with non-insulin dependent diabetes mellitus

1982 ◽  
Vol 100 (3) ◽  
pp. 410-415 ◽  
Author(s):  
Leif Groop ◽  
Karl Johan Tötterman
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Secretion ◽  
Blood Glucose ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Double Blind ◽  
C Peptide ◽  
Tolbutamide Test ◽  
Insulin Dependent

Abstract. In a double-blind cross-over trial we compared the effects of placebo and propranolol on iv tolbutamide and oral glipizide-stimulated insulin secretion in 10 noninsulin dependent diabetics. The patients were randomly allocated for 2 weeks treatment with placebo and propranolol 80 mg twice daily. At the end of each period an iv tolbutamide test and an oral glipizide-glucose-test were performed. Tolbutamide-stimulated insulin secretion was not affected by propranolol. There was no change in blood glucose levels during the iv tolbutamide test (IVTT), which excluded an effect of blood glucose on insulin secretion. During the oral glipizide-glucose challenge propranolol decreased blood glucose at 60 min (P < 0.01) and increased C-peptide at 0 min (P < 0.01) and 30 min (P < 0.05) compared with placebo. In contrast to earlier results obtained in animals and healthy subjects propranolol does not inhibit insulin- or C-peptide responses to sulphonylurea in patients with non-insulin dependent diabetes mellitus.

Personal Illness Models of Diabetes: Preadolescents and Adolescents

1997 ◽  
Vol 23 (2) ◽  
pp. 147-151 ◽  
Author(s):  
Debra A. Standiford ◽  
Angela M. Turner ◽  
Susan R. Allen ◽  
Debra J. Drozda ◽  
Gail C. McCain
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Healthcare Professionals ◽  
Research Study ◽  
Insulin Dependent Diabetes Mellitus ◽  
Dependent Diabetes Mellitus ◽  
Questionnaire Data ◽  
Cognitive Representations ◽  
Insulin Dependent

The purpose of this research study was to explore personal illness models of preadolescents and adolescents regarding diabetes mellitus. Personal illness models were defined as the adolescents' cognitive representations of their disease. Sixty children ages 10 to 17 years with a diagnosis of insulin- dependent diabetes mellitus were interviewed using a semistructured questionnaire. Data were content analyzed for common themes. Although most participants expressed an understanding that their disease would last a lifetime, they were hopeful for a cure. Participants wanted healthcare professionals to provide strategies for controlling blood glucose to prevent future complications. Family and friends who followed the same diet as the adolescent with diabetes were viewed as supportive. The majority of adolescents were responsible for much of their own disease management. Their greatest fears concenled insulin reactions and long-term complications such as amputation of limbs.

Oral hypoglycaemics for diabetes: when and which?

1991 ◽  
Vol 29 (4) ◽  
pp. 13-16
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Regular Exercise ◽  
Control Blood Glucose ◽  
District Policy ◽  
Insulin Dependent ◽  
Market Leader

People with non-insulin-dependent diabetes mellitus should modify their diet, avoid obesity and take regular exercise. An oral hypoglycaemic drug may be needed if these measures fail to control blood glucose, but it is now clear that they commonly cause hypoglycaemia. More than 3 million prescriptions were issued in 1988 for the sulphonylureas (eight currently available) and the biguanide, metformin. Glibenclamide is the market leader (1.4 million prescriptions in 1988), followed by metformin (950,000), chlorpropamide (280,000), tolbutamide (260,000) and gliclazide (200,000). Instituting a district policy to restrict the choice of sulphonylureas can improve care and save money.1 No new oral hypoglycaemics have been marketed since we last reviewed them2 but their place in overall management has been clarified.

Sign in / Sign up

Export Citation Format

Share Document